A well known phenomenon of the Covid-19 era is that the deadly virus presents a wide disparity of symptoms between patients – now a Triangle firm has the federal funding to try to find out why. Last week, Morrisville-based Metabolon was selected by the National Institute of Allergy and Infectious Diseases (NIAID) to be a lead in its "Immunophenotyping Assessment in a Covid-19 Cohort," or IMPACC, study.